# Strict IGF-1 Control in Acromegaly

Source: https://onco.cc/trials/nct02952885/  
OnCo record `nct02952885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pegvisomant in Pituitary tumours, run by Unity Health Toronto, completed.

## Summary

Strict IGF-1 Control in Acromegaly is a phase 3 interventional study registered as NCT02952885 by Unity Health Toronto, with 10 participants recorded, started 2017-07-27 and reaching its primary completion in 2020-05-07. Interventions recorded: Pegvisomant. Conditions recorded: Acromegaly.

Linked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02952885
- Phase: 3
- Setting: Strict IGF-1 Control in Acromegaly (I-Con Study)
- Sponsor: Unity Health Toronto
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT02952885: https://clinicaltrials.gov/study/NCT02952885

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Pegvisomant](https://onco.cc/drugs/pegvisomant/)

---
JSON: https://onco.cc/api/v1/entities/nct02952885.json